LY3556050 + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Peripheral Neuropathic Pain
Conditions
Diabetic Peripheral Neuropathic Pain
Trial Timeline
May 6, 2021 → Jun 13, 2022
NCT ID
NCT04707157About LY3556050 + Placebo
LY3556050 + Placebo is a phase 2 stage product being developed by Eli Lilly for Diabetic Peripheral Neuropathic Pain. The current trial status is terminated. This product is registered under clinical trial identifier NCT04707157. Target conditions include Diabetic Peripheral Neuropathic Pain.
What happened to similar drugs?
20 of 20 similar drugs in Diabetic Peripheral Neuropathic Pain were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06074562 | Phase 2 | Completed |
| NCT04874636 | Phase 2 | Completed |
| NCT04707157 | Phase 2 | Terminated |
| NCT04627038 | Phase 2 | Completed |
| NCT05341102 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetic Peripheral Neuropathic Pain